GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BioMerieux SA (WBO:BIM) » Definitions » Deferred Policy Acquisition Costs

BioMerieux (WBO:BIM) Deferred Policy Acquisition Costs


View and export this data going back to 2020. Start your Free Trial

What is BioMerieux Deferred Policy Acquisition Costs?

Deferred Policy Acquisition Costs only applies to banks and insurance companies.


BioMerieux (WBO:BIM) Business Description

Traded in Other Exchanges
Address
Marcy l’Etoile, Lyon, FRA, 69280
BioMerieux designs, develops, and manufactures a broad portfolio of in vitro diagnostics for detecting disease-causing pathogens and contamination. The company operates in four segments: molecular biology (38% of 2021 sales), microbiology (31%), immunoassays (14%), and industrial applications (about 17%). The Americas account for the largest portion of the firm's revenue (49%), followed by Europe, the Middle East, and Africa (33%), and Asia-Pacific (18%). BioMerieux is headquartered in Marcy-l'Etoile, France.